NGS Combined With RNAseq on Tumor Immune Escape in NSCLC

Non-small Cell Lung Cancer Clinical Trial

Official title:

Study on the Effect of NGS Combined With RNAseq on Tumor Immune Escape in Advanced Non-small Cell Lung Cancer EGFR and ALK Mutant Negative Patients

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03764917
• Other study ID #: YS2018-003
• Status: Active, not recruiting
• Start date: December 1, 2018
• Est. completion date: December 31, 2021

Study information

• Verified date: March 2020
• Source: Shanghai Pulmonary Hospital, Shanghai, China
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq

Description:

Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq. Detecting non-small cell lung cancer patient NGS and RNAseq data before first-line chemotherapy, after two cycles chemotherapy and after disease progression.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 100
• Est. completion date: December 31, 2021
• Est. primary completion date: December 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

Non-small cell lung cancer patient First-line chemotherapy with platinum-based chemotherapy

Exclusion Criteria:

EGFR mutant positive Alk mutant positive

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Other:
• Time
Different detecting time

Locations

Country	Name	City	State
China	Shanghai Pulmonary Hospital	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Pulmonary Hospital, Shanghai, China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	numbers of immune cells	detecting numbers of immune cells before first-line chemotherapy, after two cycles chemotherapy and after disease progression	24 months
Secondary	numbers of tumor mutations	detecting numbers of tumor mutations before first-line chemotherapy, after two cycles chemotherapy and after disease progression	24 months